Hong Kong Launches Inaugural HIV Testing Month to Combat AIDS Awareness and Prevention

2024-11-30 15:48 Last Updated At：15:58

DH holds World AIDS Campaign 2024 Kick-off Ceremony to promote prevention of HIV infection and inaugural HIV Testing Month

The Department of Health (DH) and Hong Kong Advisory Council on AIDS (ACA) today (November 30) jointly held the World AIDS Campaign 2024 Kick-off Ceremony to raise public awareness of the prevention of Human Immunodeficiency Virus (HIV) infection. The DH also announced the launch of the inaugural HIV Testing Month in Hong Kong, encouraging people who have had sex to undergo HIV testing at least once to keep track of their own health status. People with HIV should seek specialist care and HIV treatment as soon as possible for viral suppression and for health restoration.

The World Health Organization (WHO) has designated December 1 (i.e. tomorrow) each year as World AIDS Day, and today's event was organised in response to this observance. Under the theme "Advances with Love, 40 Years of United Actions & Beyond", the ceremony reflected on the past and future joint efforts between the Government, healthcare sector and non-governmental organisations (NGOs) to combat AIDS and care for patients and their families through a multipronged approach and strategic collaboration since the first case of HIV infection was reported in Hong Kong in 1984.

Officiating at the ceremony, the Director of Health, Dr Ronald Lam, said, "The prevalence of HIV infection in Hong Kong remains well below the global average, accounting for 1 in 1 000 of the adult population. The number of new cases in recent years has continued to drop from the peak in 2015, which is encouraging. However, we must not be complacent, as the proportion of late presenters in Hong Kong has been on the rise in recent years, and the number of newly infected persons aged 50 or above has not dropped in tandem with the overall number of newly infected persons. Furthermore, various challenges such as stigma and discrimination still exist."

In view of this, the Red Ribbon Centre of the DH, in collaboration with 12 NGOs and 10 supporting organisations, is launching the inaugural HIV Testing Month in Hong Kong in December (i.e. from tomorrow onwards), with a view to increasing the public's awareness of HIV testing in Hong Kong, as well as helping the public understand how to get tested for HIV easily and conveniently through a variety of channels.

The Scientific Committee on AIDS and STI has earlier issued its recommendation that people who have had sex should get HIV testing at least once.

Dr Lam said, "The launch of HIV Testing Month aims to promote the normalisation of HIV testing. Members of the public can browse the HIV Testing Service website (www.hivtest.gov.hk) or access the HIV testing calendar on the HIV Testing Service website via the '@DH mobile application' to learn more about and select testing resources in the community."

The Government will launch a new Announcement of Public Interest (API) under the slogan "For your health, get tested for HIV" to appeal to people who have had sex to get tested for HIV at least once, so that those who are unaware of their infection status can receive timely diagnosis and treatment. Normalising HIV testing will also help remove the negative stigma associated with HIV infection and testing.

The ceremony was attended by around 100 stakeholders who have been involved in the fight against AIDS since the 1980s.

Designated as a United Nations Programme on HIV/AIDS (UNAIDS) Collaborating Centre for Technical Support, the Red Ribbon Centre of the DH has been working closely with NGOs involved in AIDS work to promote the World AIDS Campaign. It will continue to conduct publicity and education through different channels to raise public awareness of AIDS prevention.

Other officiating guests at the ceremony included the Controller of the Centre for Health Protection of the DH, Dr Edwin Tsui; the Director of the Centre for Health Systems and Policy Research of the JC School of Public Health and Primary Care of the Chinese University of Hong Kong, Professor Yeoh Eng-kiong; the Chairman of the Hong Kong AIDS Foundation, Dr Leong Che-hung; the Chairperson of the ACA, Dr Ho King-man; the Chairman of the Expert Panel on HIV Infection of Health Care Workers, Dr Lai Sik-to; and the Chairman of the Scientific Committee on AIDS and STI, Dr Lee Cheuk-kwong.

Hong Kong’s Health Department Launches 1+ Mechanism for Faster Drug Registration and Improved Industry Collaboration

2025-04-01 12:15 Last Updated At：12:38

DH's first briefing seminar on "1+" mechanism for new drugs well received

The Department of Health (DH) yesterday (March 31) held the first briefing seminar on the "1+" mechanism for new drugs with an introduction of the requirements for registration of pharmaceutical products under this mechanism, as well as the upcoming workshops on good regulatory practices and pre-new drug application (NDA) meetings. The DH aims to work with the pharmaceutical industry to achieve the goals of early consultation to enhance quality and efficiency throughout the process so that registration approval can be expedited, thereby bringing more good drugs for use in Hong Kong.

"The Chief Executive's 2024 Policy Address" announced that a consultation service for NDAs under the "1+" mechanism will be introduced to enhance the efficiency of processing relevant applications. The consultation service comprises briefing seminars, workshops and pre-NDA meetings. Yesterday's seminar was well received and was attended by 76 representatives from pharmaceutical and consultation companies inside or outside Hong Kong, as well as scientific research institutions. This marks the beginning of the consultation service. The DH will organise two more seminars on April 21 and May 16 this year. For further details and to register for future seminars, please visit the Drug Office's thematic webpage on the "1+" mechanism.

The DH will also organise workshops starting from June this year to provide guidance and sharing of good practices and real-life experiences on submitting applications through the "1+" mechanism. The DH will also offer to hold pre-NDA meetings with potential "1+" registration applicants starting from the second half of this year, providing specific guidance to assist in their planning of the NDA approval process and improve the quality of application documents to enhance the efficiency of the whole process. Details of the arrangements of the workshops and meetings will be announced in due course.

The Hong Kong Special Administrative Region (HKSAR) Government has implemented the "1+" mechanism since November 1, 2023, to facilitate the registration of new drugs for treating life-threatening or severely debilitating diseases in Hong Kong. The HKSAR Government has extended the "1+" mechanism to all new drugs from November 1, 2024, including all new chemical or biological entities and new indications, and vaccines and advanced therapy products. Under the "1+" mechanism, new drugs which are supported by local clinical data and recognised by local relevant experts can be applied for registration in Hong Kong by submitting approval from the drug regulatory authority of one of the reference places (instead of two in the past).

The "1+" mechanism serves to attract more new drugs from different parts of the world seeking approval for registration in Hong Kong, giving patients more choices and further strengthening the local capacity for drug evaluation while enhancing the development of relevant software, hardware and expertise with a view to progressing towards "primary evaluation". Since the implementation of the "1+" mechanism, a total of 11 new drugs have been approved under this mechanism. The DH has been promoting the "1+" mechanism through different channels, and so far, has received 460 enquiries from 120 pharmaceutical companies, including those from overseas and the Mainland.

Meanwhile, the Government will continue its efforts to reform the approval mechanism for drugs and medical devices. These include putting forward a timetable for establishing the Hong Kong Centre for Medical Products Regulation and charting a roadmap towards "primary evaluation" in the first half of this year, aiming to spur the growth of new industries in pharmaceutical and medical device research, and development and testing.